These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25682597)

  • 1. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
    Konopleva M; Thall PF; Yi CA; Borthakur G; Coveler A; Bueso-Ramos C; Benito J; Konoplev S; Gu Y; Ravandi F; Jabbour E; Faderl S; Thomas D; Cortes J; Kadia T; Kornblau S; Daver N; Pemmaraju N; Nguyen HQ; Feliu J; Lu H; Wei C; Wilson WR; Melink TJ; Gutheil JC; Andreeff M; Estey EH; Kantarjian H
    Haematologica; 2015 Jul; 100(7):927-34. PubMed ID: 25682597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
    Fraser C; Brown P; Megason G; Ahn HS; Cho B; Kirov I; Frankel L; Aplenc R; Bensen-Kennedy D; Munteanu M; Weaver J; Harker-Murray P
    J Pediatr Hematol Oncol; 2014 May; 36(4):e212-8. PubMed ID: 24072240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
    Jameson MB; Rischin D; Pegram M; Gutheil J; Patterson AV; Denny WA; Wilson WR
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):791-801. PubMed ID: 20012293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
    Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-Ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock R; Andreeff M; Konopleva M
    PLoS One; 2011; 6(8):e23108. PubMed ID: 21853076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix.
    Jankovic B; Aquino-Parsons C; Raleigh JA; Stanbridge EJ; Durand RE; Banath JP; MacPhail SH; Olive PL
    Cytometry B Clin Cytom; 2006 Mar; 70(2):45-55. PubMed ID: 16456867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia and expression of hypoxia-related proteins in acute myeloid leukemia.
    Fiegl M; Spiekermann K
    Leuk Res; 2011 May; 35(5):573-4. PubMed ID: 21163529
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
    Hoogsteen IJ; Lok J; Marres HA; Takes RP; Rijken PF; van der Kogel AJ; Kaanders JH
    Eur J Cancer; 2009 Nov; 45(16):2906-14. PubMed ID: 19699082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of temozolomide in relapsed/refractory acute leukemia.
    Seiter K; Liu D; Loughran T; Siddiqui A; Baskind P; Ahmed T
    J Clin Oncol; 2002 Aug; 20(15):3249-53. PubMed ID: 12149298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
    Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
    Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
    Said HM; Polat B; Staab A; Hagemann C; Stein S; Flentje M; Theobald M; Katzer A; Vordermark D
    Oncol Rep; 2008 Aug; 20(2):413-9. PubMed ID: 18636206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
    Uy GL; Hsu YM; Schmidt AP; Stock W; Fletcher TR; Trinkaus KM; Westervelt P; DiPersio JF; Link DC
    Leuk Res; 2015 Dec; 39(12):1437-42. PubMed ID: 26467815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathomorphosis of acute leukemia].
    Popov VM
    Sov Med; 1991; (9):15-8. PubMed ID: 1724709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of carbonic anhydrase IX in craniopharyngiomas.
    Proescholdt M; Merrill M; Stoerr EM; Lohmeier A; Dietmaier W; Brawanski A
    J Neurosurg; 2011 Oct; 115(4):796-801. PubMed ID: 21761968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
    Rayes A; McMasters RL; O'Brien MM
    Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.